Genascence competitors & alternatives

Regenerative Medicine

NellOne Therapeutics develops regenerative-medicine therapies based on NELL-1, a protein associated with bone formation and regeneration. Its work is aimed at treating bone defects and related orthopedic conditions for patients and healthcare providers.

Drug Discovery

Sarcomatrix Therapeutics Corp. is a biopharmaceutical and biotechnology research company headquartered in Reno, Nevada. The company is dedicated to pioneering muscle regeneration therapies and advancing novel therapeutics to treat muscle-wasting diseases.

OsteoCure TherapeuticsRegenerative MedicineUnited States

64% match

Regenerative Medicine

OsteoCure Therapeutics is a biotechnology research company and Duke University spinout headquartered in Durham, North Carolina, developing first-in-class adenosine-based biologics to restore skeletal health.

MendraBiopharmaceuticalsUnited States

64% match

Biopharmaceuticals

Mendra is a venture-backed biotechnology research startup established in 2025 and headquartered in San Francisco, focused on accelerating the development and commercialization of rare disease therapies.

Scout Bio, Inc.BiopharmaUnited States

64% matchPrivate

Biopharma

Scout Bio, Inc. is a veterinary biotechnology company specializing in animal health and advanced gene therapy treatments currently being evaluated in clinical trials.

LUCA ScienceDrug DiscoveryJapan

64% match

Drug Discovery

LUCA Science is a pre-clinical stage biotechnology company that develops functional mitochondria as therapeutic agents to treat damaged tissues and organs. The company utilizes a proprietary method to isolate functional mitochondria, combining it with advanced drug delivery and formulation technology to create storable biopharmaceutical agents.

Drug Discovery

Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.

Drug Discovery

VectorY Therapeutics is a fully integrated gene therapy company founded in August 2020 and based in Amsterdam, Netherlands. The company is focused on developing novel gene therapies, including clinical trials for conditions like amyotrophic lateral sclerosis (ALS).

VersamebDrug DiscoverySwitzerland

63% match

Drug Discovery

Versameb AG is a privately held biopharmaceutical company focused on discovering and developing innovative RNA-based therapeutics.

BridgeBio Pharma, Inc.BBIO · BiopharmaceuticalsPalo Alto, United States

63% matchPublicAI 34/100Green 2/100

Biopharmaceuticals

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Biopharmaceutical

Lerna Biopharma, formerly known as Cargene Therapeutics, is a preclinical-stage biopharmaceutical company founded in 2020. The company develops innovative RNA and oligonucleotide therapeutics, including siRNA, utilizing proprietary nucleic acid technologies and delivery platforms to address liver diseases and promote tissue regeneration.

Genomic Engineering

Synthego Holdings LLC is a biotechnology and CRISPR solutions company headquartered in Redwood City, California. It delivers cutting-edge molecular diagnostics and tools designed to accelerate life science research and development for improved human health.